These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 695577)

  • 1. [Antithrombin III in the light of modern concepts].
    Dmoszyńska A; Pluta A
    Wiad Lek; 1978 May; 31(10):677-80. PubMed ID: 695577
    [No Abstract]   [Full Text] [Related]  

  • 2. Actions and interactions of antithrombin and heparin.
    Rosenberg RD
    N Engl J Med; 1975 Jan; 292(3):146-51. PubMed ID: 127943
    [No Abstract]   [Full Text] [Related]  

  • 3. [Evaluation of the nature and dynamics of changes in hemostasis in myocardial infarct. I. Antithrombin III and endogenous heparin activities].
    Zapolska-Downar D; Borodin M; Gregorczyk J; Chełstowski K; Sprogis W
    Przegl Lek; 1988; 45(4):387-91. PubMed ID: 3212203
    [No Abstract]   [Full Text] [Related]  

  • 4. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anticoagulating activity and lytic action of the heparin-antithrombin III and antithrombin III-heparin-thrombin complexes on non-stabilized fibrin].
    Kudriashov BA; Pastorova VE; Liapina LA
    Biokhimiia; 1981 Nov; 46(11):2024-9. PubMed ID: 7317530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanisms of heparin resistance and their clinical significance].
    Barkagan ZS; Lychev VG; Bishevskiĭ KM; Tsyvkina LP; Glazunova GA
    Ter Arkh; 1982; 54(8):77-82. PubMed ID: 6753220
    [No Abstract]   [Full Text] [Related]  

  • 7. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The physiological inhibitors of blood coagulation. 1. Antithrombin III (AT III)].
    Kase F; Pospísil J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(3):337-49. PubMed ID: 6194066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of heparin with thrombin and antithrombin III.
    Feinman RD; Li EH
    Fed Proc; 1977 Jan; 36(1):51-5. PubMed ID: 830556
    [No Abstract]   [Full Text] [Related]  

  • 11. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.
    Ofosu FA; Cerskus AL; Hirsh J; Smith LM; Modi GJ; Blajchman MA
    Br J Haematol; 1984 Jun; 57(2):229-38. PubMed ID: 6733045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of the antithrombin III-heparin-thrombin complex in the defense reaction of the anticoagulation system].
    Kudriashov BA; Liapina LA; Pastorova VE
    Vopr Med Khim; 1988; 34(2):38-42. PubMed ID: 3400189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progressively acting antithrombins and plasma heparin resistance in ischemic heart disease].
    Barkagan ZS; Bishevskiĭ KM; Vidiakov GE; Kungurov IA
    Kardiologiia; 1981 Aug; 21(8):31-5. PubMed ID: 7289382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal antithrombin III (antithrombin III "Budapest") as a cause of a familial thrombophilia.
    Sas G; Blaskó G; Bánhegyi D; Jákó J; Pálos LA
    Thromb Diath Haemorrh; 1974 Sep; 32(1):105-15. PubMed ID: 4454033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The consumption of antithrombin III during coagulation, its consequences for the calculation of prothrombinase activity and the standardisation of heparin activity.
    Béguin S; Kessels H; Dol F; Hemker HC
    Thromb Haemost; 1992 Aug; 68(2):136-42. PubMed ID: 1412157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
    Meddahi S; Bara L; Fessi H; Samama MM
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-thormbin III and heparin clotting times in thrombosis and atherosclerosis.
    O'Brien JR
    Thromb Diath Haemorrh; 1974 Sep; 32(1):116-23. PubMed ID: 4454034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interaction of proteases, antithrombin III, and heparin.
    Downing MR
    J Lab Clin Med; 1980 Jun; 95(6):777-82. PubMed ID: 6991619
    [No Abstract]   [Full Text] [Related]  

  • 19. [Heparin].
    Roszkowska W; Worowski K
    Postepy Hig Med Dosw; 1984; 38(1):73-124. PubMed ID: 6387687
    [No Abstract]   [Full Text] [Related]  

  • 20. [Inhibitors of the serine-proteases of coagulation with special reference to antithrombin III and heparin cofactor II].
    Fontcuberta J
    Sangre (Barc); 1985; 30(4-C):787-91. PubMed ID: 3841417
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.